Synthetic approaches for novel annulated pyrido[2,3-d]pyrimidines: Design, Structural Characterization, Fukui functions, DFT Calculations, Molecular docking and Anticancer efficiency

Journal of Molecular Structure, Год журнала: 2024, Номер 1318, С. 139335 - 139335

Опубликована: Июль 18, 2024

Язык: Английский

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Cells, Год журнала: 2024, Номер 13(19), С. 1656 - 1656

Опубликована: Окт. 6, 2024

Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. These received substantial FDA clearance recent decades. emerged as primary objectives for therapeutic interventions, particularly context treatment. At present, 69 therapeutics been approved that target approximately 24 kinases, which are specifically prescribed neoplastic illnesses. novel agents inhibit certain such receptor protein-tyrosine protein-serine/threonine dual-specificity nonreceptor kinases. This review presents a comprehensive overview targets inhibitors, with specific focus on cyclin-dependent (CDKs) epidermal growth factor (EGFR). majority reviewed studies commenced an assessment cell lines concluded biological evaluation individual targets. articles provide detailed information structural features potent anticancer activity, refers ability selectively cancer-promoting including CDKs EGFR. Additionally, latest FDA-approved targeting these enzymes were highlighted accordingly.

Язык: Английский

TiO2 Nanoparticles Catalyzed Synthesis, Pharmacological Evaluation, and Molecular Docking Studies of New Pyrido[2,3-d]Pyrimidine Derivatives as CDK1 Inhibitors

Chemistry Africa, Год журнала: 2025, Номер unknown

Опубликована: Март 9, 2025

Язык: Английский